GT Biopharma, Inc. (GTBP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q1 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '15 Q3 '16 Q2 '17 Q1 '18 Q1 '20 Q4 '20 Q3 '21

Gross Profit Quarterly

-7K 0 7K 14K 21K Q1 '14: 0 Q2 '14: 8K Q3 '14: -2K Q4 '14: -2K Q1 '15: 7K Q2 '15: 20K Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q1 '19: 0 Q1 '20: 0 Q2 '14 Q1 '15 Q4 '15 Q3 '16 Q2 '17 Q1 '18 Q1 '20

Operating Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '21: -6M Q4 '21: -18.2M Q1 '22: -5.4M Q2 '22: -3M Q3 '22: -7M Q4 '22: -5.8M Q1 '23: -3.7M Q2 '23: -3.6M Q3 '23: -3.1M Q4 '23: -3.2M Q1 '24: -3.1M Q2 '24: -3.9M Q3 '24: -3.6M Q4 '24: -3.8M Q1 '25: -1.9M Q2 '25: -1.5M Q3 '25: -3.4M Q4 '25: -5.6M Q1 '26: -2.8M Q2 '26: -4.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -5.5M Q4 '21: -18M Q1 '22: -5.4M Q2 '22: -3M Q3 '22: -6.9M Q4 '22: -5.6M Q1 '23: -227K Q2 '23: -2M Q3 '23: -2.4M Q4 '23: -3M Q1 '24: -2.3M Q2 '24: -3.7M Q3 '24: -3.4M Q4 '24: -3.8M Q1 '25: -776K Q2 '25: -30.2M Q3 '25: 8.3M Q4 '25: -7.5M Q1 '26: -2.8M Q2 '26: -4.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 15K 30K 45K Q1 '14: 0 Q2 '14: 17K Q3 '14: 5K Q4 '14: 35K Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q1 '19: 0 Q1 '20: 0 Q2 '14 Q1 '15 Q4 '15 Q3 '16 Q2 '17 Q1 '18 Q1 '20

Operating Cash Flow Quarterly

-6M -4M -2M 0 2M 4M 6M Q3 '21: -3.9M Q4 '21: -3.7M Q1 '22: -5.2M Q2 '22: -2.8M Q3 '22: -2.9M Q4 '22: -4.3M Q1 '23: -2.9M Q2 '23: -1.9M Q3 '23: -2M Q4 '23: -2M Q1 '24: -4.2M Q2 '24: -3.5M Q3 '24: -2.7M Q4 '24: -2.5M Q1 '25: -2.2M Q2 '25: -3M Q3 '25: -3.7M Q4 '25: -4M Q1 '26: -2.5M Q2 '26: -4.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q1 '17: -650K Q2 '17: -391K Q3 '17: -2.2M Q4 '17: -2.2M Q1 '18: -4.2M Q2 '18: -1.8M Q3 '18: -3.4M Q4 '18: -1.3M Q1 '19: -961K Q2 '19: -1.1M Q3 '19: -1.1M Q4 '19: -485K Q2 '17 Q4 '17 Q2 '18 Q4 '18 Q2 '19 Q4 '19

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q3 '18: 50.2M Q1 '19: 51.1M Q1 '20: 70.1M Q1 '21: 16.2M Q2 '21: 33.5M Q3 '21: 31.4M Q1 '22: 32.5M Q2 '22: 31.2M Q3 '22: 31.4M Q1 '23: 1.1M Q2 '23: 1.3M Q3 '23: 1.4M Q1 '24: 1.4M Q2 '24: 1.7M Q3 '24: 2.2M Q1 '25: 2.3M Q2 '25: 2.8M Q3 '25: 3.9M Q1 '26: 30.3M Q2 '26: 38.8M Q1 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q3 '21: -8.30 Q4 '21: -2.67 Q1 '22: -1.01 Q2 '22: -0.96 Q3 '22: -1.01 Q4 '22: -19.67 Q1 '23: -19.71 Q2 '23: -21.10 Q3 '23: -22.65 Q4 '23: -5.64 Q1 '24: -7.07 Q2 '24: -7.75 Q3 '24: -7.51 Q4 '24: -7.00 Q1 '25: -5.69 Q2 '25: -14.44 Q3 '25: -11.87 Q4 '25: -6.68 Q1 '26: -6.46 Q2 '26: 4.34 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.